All posts by: Michael Zand

About Michael Zand

Gene therapy using ‘junk DNA’ could lower risk for heart disease – UCLA Newsroom

Continue reading

2017-08-30 NEWS

UCLA Newsroom

Gene therapy using ‘junk DNA’ could lower risk for heart disease
UCLA Newsroom
Scientists from UCLA and the Howard Hughes Medical Institute successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce plaque in mice with a disorder called familial hypercholesterolemia. In a preclinical study

Continue reading

2017-08-30 NEWS

New Scientist

FDA approval brings first gene therapy to the United States
FDA.gov
The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved …
Pioneering gene therapy approved for leukaemia in the USNew Scientist
FDA Approves Groundbreaking Gene Therapy for CancerMIT Technology Review
Hailing a breakthrough in fighting cancer, FDA approves gene therapy that functions as a ‘living drug’Los Angeles Times
NPR –National Cancer Institute
all 656 news articles »
Continue reading

2017-08-30 NEWS

Probiotic, peanut oral immunotherapy provides long-lasting clinical benefit
Healio
Combined probiotic and peanut oral immunotherapy delivered long-lasting clinical benefit and long-term repression of the allergic immune response to peanut, according to findings recently published in The Lancet: Child & Adolescent Health. “The quality

Continue reading

2017-08-30 NEWS

San Francisco Chronicle

Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
Nasdaq
Biotech giant Gilead Sciences, Inc. ‘s GILD $11.8 billion deal to buy CART cancer therapy designer, Kite Pharma, Inc. KITE has made two other leading independent CART developers, Juno Therapeutics, Inc. JUNO and Bluebird Bio, Inc. BLUE hot takeover …
Gilead to Fly High with Kite Pharma Acquisition for $11.9BYahoo Finance
‘Game-changer’ cancer treatment is focus of Gilead’s $12 billion cell therapy dealSan Francisco Chronicle
Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma ClosesLymphoma News Today
GeekWire –Washington Post –Arkansas Online –Zacks Investment Research
all 137 news articles »
Continue reading

2017-08-30 NEWS

Medical Xpress

Nanoparticles loaded with mRNA give disease-fighting properties to cells
Medical Xpress
A diagram of a scaffold loaded with CAR T cells and “microspheres” containing nutrients to help the cells multiply and then leave the scaffold to go attack cancer cells. Credit: Cognition Studio, courtesy of Fred Hutchinson Cancer Research Center.
New nanoparticles make targeted, temporary gene therapy possibleFred Hutch News Service

all 2 news articles »